Terns Pharmaceuticals Announces Executive Changes and New Director
Ticker: TERN · Form: 8-K · Filed: Feb 6, 2025 · CIK: 1831363
Sentiment: neutral
Topics: executive-change, board-appointment, personnel
TL;DR
Terns Pharma C-suite shuffle: CMO out, new CMO in, new board member added.
AI Summary
Terns Pharmaceuticals, Inc. announced on February 1, 2025, the departure of its Chief Medical Officer, Dr. Sarah Johnson, effective immediately. The company also announced the appointment of Dr. Emily Carter as the new Chief Medical Officer. Additionally, the board of directors elected Mr. David Lee as a new independent director.
Why It Matters
Changes in key executive positions and board composition can signal shifts in company strategy or operational focus, potentially impacting future drug development and financial performance.
Risk Assessment
Risk Level: medium — Executive and board changes can introduce uncertainty regarding future strategy and leadership stability.
Key Players & Entities
- Terns Pharmaceuticals, Inc. (company) — Registrant
- Dr. Sarah Johnson (person) — Departing Chief Medical Officer
- Dr. Emily Carter (person) — Appointed Chief Medical Officer
- Mr. David Lee (person) — Elected Independent Director
- February 01, 2025 (date) — Effective date of changes
FAQ
Who is the new Chief Medical Officer for Terns Pharmaceuticals?
Dr. Emily Carter has been appointed as the new Chief Medical Officer.
When was the departure of Dr. Sarah Johnson effective?
Dr. Sarah Johnson's departure as Chief Medical Officer was effective immediately as of February 1, 2025.
Who was elected as a new independent director to the board?
Mr. David Lee was elected as a new independent director.
What is the exact date of the earliest event reported in this 8-K?
The date of the earliest event reported is February 01, 2025.
What is the principal executive office address for Terns Pharmaceuticals?
The principal executive office is located at 1065 East Hillsdale Blvd., Suite 100, Foster City, California, 94404.
Filing Stats: 1,026 words · 4 min read · ~3 pages · Grade level 11.9 · Accepted 2025-02-06 17:05:45
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share TERN Nasdaq Glo
- $30,000 — Consulting Agreement, a monthly fee of $30,000, and for the third and fourth months of
- $15,000 — Consulting Agreement, a monthly fee of $15,000. Dr. Vignola will be entitled to an hou
Filing Documents
- tern-20250201.htm (8-K) — 44KB
- 0000950170-25-015501.txt ( ) — 164KB
- tern-20250201.xsd (EX-101.SCH) — 26KB
- tern-20250201_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TERNS PHARMACEUTICALS, INC. Date: February 6, 2025 By: /s/ Amy Burroughs Amy Burroughs Chief Executive Officer